Alterations of PI3K/AKT signalling pathway play essential role in endometrial carcinogenesis and currently a number of clinical trials are underway to assess the effectiveness of therapies using PI3K/Akt pathway inhibitors.10 The PI3K/AKT pathway is frequently activated in endometrial carcinoma, often due to PTEN loss. The gene discussed is PTEN; the disease is endometrial carcinoma.